Home·Explore by biomarker·MET

MET

Biomarker

MET is a receptor tyrosine kinase involved in cell growth and survival. Exon skipping mutations and amplifications are actionable in lung and other cancers.

Approvals
4
Indications
1
Therapies
3
Mapped tests
3

Where this biomarker is used

Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.

Indication-specific approvals

Approvals where MET is defined directly in the indication labeling.

IndicationBiomarker criteriaTherapies
Non-Small Cell Lung Cancer (NSCLC)
Solid Tumor · Lung
  • MET protein expression (>= 50% of tumor cells exhibiting strong membrane and/or cytoplasmic staining 3+)
  • single nucleotide variants and indels that lead to MET exon 14 skipping
EMRELISTEPMETKOTABRECTA
Tumor-agnostic approvals

Approvals defined at the solid tumor level where MET is part of the eligibility criteria.

No tumor-agnostic approvals are currently mapped for this biomarker.

Tests that measure this biomarker

These assays report MET as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.

Test
FoundationOne CDx
Foundation Medicine, Inc.
Method
NGS
Specimen
Tissue (FFPE)

Reports MET as part of its biomarker panel.

1 approvalView test profile →
Test
FoundationOne Liquid CDx
Foundation Medicine, Inc.
Method
NGS
Specimen
Whole blood

Reports MET as part of its biomarker panel.

2 approvalsView test profile →
Test
Ventana MET (SP44) RxDx Assay
Ventana Medical Systems, Inc.
Method
IHC
Specimen
Tissue (FFPE)

Reports MET as part of its biomarker panel.

1 approvalView test profile →
This view is scoped to MET. You can also see how it compares with other biomarkers and indications on the Know Your Companions™ map.